Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide

被引：0

作者：

Orkin, Chloe ^{[1
]}

Antinori, Andrea ^{[2
]}

Rockstroh, Juergen ^{[3
]}

Guillen, Santiago Moreno ^{[4
]}

Martorell, Claudia ^{[5
]}

Molina, Jean-Michel ^{[6
]}

Lazzarin, Adriano ^{[7
]}

Maggiolo, Franco ^{[8
]}

Yazdanpanah, Yazdan ^{[9
]}

Andreatta, Kristen ^{[10
]}

Huang, Hailin ^{[10
]}

Hindman, Jason ^{[10
]}

Martin, Hal ^{[10
]}

Baeten, Jared ^{[10
]}

Pozniak, Anton ^{[11
]}

机构：

[1] Queen Mary Univ London, London, England

[2] Natl Inst Infect Dis, Lazzaro Spallanzani, Rome, Italy

[3] Univ Hosp Bonn, Bonn, Germany

[4] Hosp Ramon & Cajal, Madrid, Spain

[5] Res Inst Springfield, Springfield, MO USA

[6] Univ Paris, Paris, France

[7] San Raffaele Hosp Milan, Milan, Italy

[8] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy

[9] AP HP Hop Bichat, Paris, France

[10] Gilead Sci Inc, Foster City, CA USA

[11] Chelsea & Westminster Hosp, London, England

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

P002

引用

页码：21 / 22

页数：2

共 50 条

[41] Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Stellbrink, Hans-Juergen
Arribas, Jose R.
Stephens, Jeffrey L.
Albrecht, Helmut
Sax, Paul E.
Maggiolo, Franco
Creticos, Catherine
Martorell, Claudia T.
Wei, Xuelian
Acosta, Rima
Collins, Sean E.
Brainard, Diana
Martin, Hal
LANCET HIV, 2019, 6 (06): : E364 - E372
[42] HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
D'Antoni, Michelle L.
Andreatta, Kristen
Chang, Silvia
Cox, Stephanie
Hindman, Jason T.
Avihingsanon, Anchalee
Martin, Hal
Vanderveen, Laurie A.
Callebaut, Christian
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (04) : 380 - 384
[43] Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection
Yilmaz, Aylin
Mellgren, Asa
Fuchs, Dietmar
Nilsson, Staffan
Blennow, Kaj
Zetterberg, Henrik
Gisslen, Magnus
INFECTIOUS DISEASES, 2019, 51 (11-12) : 838 - 846
[44] Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir plus abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
Tebas, Pablo
Kumar, Princy
Hicks, Charles
Granier, Catherine
Wynne, Brian
Min, Sherene
Pappa, Keith
AIDS, 2015, 29 (18) : 2459 - 2464
[45] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG) plus F/TAF or DTG plus F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
Acosta, Rima K.
Willkom, Madeleine
Andreatta, Kristen
Liu, Hui
Martin, Ross
Parvangada, Aiyappa
Martin, Hal
Collins, Sean
White, Kirsten L.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (03) : 363 - 371
[46] Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV
Saborido-Alconchel, Abraham
Serna-Gallego, Ana
Lopez-Cortes, Luis E.
Trujillo-Rodriguez, Maria
Praena-Fernandez, Juan Manuel
Dominguez-Macias, Montserrat
Lozano, Carmen
Munoz-Muela, Esperanza
Espinosa, Nuria
Roca-Oporto, Cristina
Sotomayor, Cesar
Herrero, Marta
Gutierrez-Valencia, Alicia
Lopez-Cortes, Luis F.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (09) : 2354 - 2360
[47] Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/ emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
Orkin, Chloe
DeJesus, Edwin
Ramgopal, Moti
Crofoot, Gordon
Ruane, Peter
LaMarca, Anthony
Mills, Anthony
Van der Cam, Bernard
De Wet, Joseph
Rockstroh, Jurgen
Lazzarin, Adriano
Rijnders, Bart
Podzamczer, Daniel
Thalme, Anders
Stoeckle, Marcel
Porter, Danielle
Liu, Hui
Cheng, Andrew
Quirk, Erin
SenGupta, Devi
Cao, Huyen
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[48] Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
Orkin, C.
DeJesus, E.
Ramgopal, M.
Crofoot, G.
Ruane, P.
LaMarca, A.
Mills, A.
Van der Cam, B.
De Wet, J.
Rockstroh, J.
Lazzarin, A.
Rijnders, B.
Podzamczer, D.
Thalme, A.
Stoeckle, M.
Chu, H.
Porter, D.
Liu, H.
Cheng, A.
Quirk, E.
SenGupta, D.
Cao, H.
HIV MEDICINE, 2017, 18 : 21 - 21
[49] Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients
Perez-Barragan, Edgar
Fernanda Guevara-Maldonado, Monica
Mancilla-Galindo, Javier
Kammar-Garcia, Ashuin
Ortiz-Hernandez, Alejandro
Antonio Mata-Marin, Jose
Perez-Cavazos, Samantha
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2023, 39 (10) : 511 - 517
[50] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
Hagins, Debbie
Kumar, Princy
Saag, Michael
Wurapa, Anson K.
Brar, Indira
Berger, Daniel
Osiyemi, Olayemi
Hileman, Corrilynn O.
Ramgopal, Moti N.
McDonald, Cheryl
Blair, Christiana
Andreatta, Kristen
Collins, Sean E.
Brainard, Diana M.
Martin, Hal
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (01) : 86 - 95

← 1 2 3 4 5 →